Short and Long Non-Coding RNAs in Renal Cell Carcinoma - PubMed
3 hours ago
- #Cancer Therapy
- #Renal Cell Carcinoma
- #Non-Coding RNAs
- Renal cell carcinoma (RCC) is the most frequent kidney malignancy with silent onset, high metastatic potential, and limited responsiveness to chemotherapy.
- Non-coding RNAs (ncRNAs), including miRNAs, lncRNAs, and circRNAs, play key roles in RCC tumorigenesis, progression, and therapy resistance.
- ncRNAs act as oncogenic drivers or tumor suppressors by modulating pathways like proliferation, apoptosis, angiogenesis, and immune evasion.
- Mechanistic ncRNA regulatory axes control ferroptosis, autophagy, metabolic reprogramming, and immune escape in RCC.
- Extracellular vesicles facilitate ncRNA-mediated intercellular communication, spreading therapy resistance.
- ncRNAs have diagnostic and prognostic applications, including miRNA signatures and circulating biomarkers.
- ncRNA-mediated resistance mechanisms affect targeted therapies like sunitinib, sorafenib, and axitinib.
- Therapeutic opportunities include inhibiting oncogenic ncRNAs or restoring tumor-suppressive ncRNAs to enhance drug sensitivity.